Primary endpoint more than doubled versus standard induction chemotherapy ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

A newly tested combination therapy showed a higher rate of survival compared to chemotherapy alone, according to a study published July 24 in The New England Journal of Medicine. Researchers from ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

Survival rates for childhood leukemia are improving thanks to new treatments. Acute lymphoblastic leukemia has the highest survival among all pediatric cancers, 80-85 percent. Seattle Children’s ...

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous ...